<div>
  <ul>
    <li>
      <p>
        Logik.io announced the beta launch of Cosmo AI, which claims to be the first AI solution for CPQ and Commerce, featuring Cosmo FunctionAssist, a Gen AI rule-writing assistant for simplified configuration administration.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.businesswire.com/news/home/20231205443386/en/Logik.io-Launches-Industry-First-AI-Capabilities-for-CPQ-and-Commerce">
      Press release
    </a>
  </p>
</div>


Sales Engagement Platforms

PROMINENT_CATEGORY

<div>
 <p>Logik.io has launched the beta version of Cosmo AI, reportedly the first AI solution for CPQ and Commerce. It includes Cosmo FunctionAssist, an AI tool for easing configuration administration work.</p>
</div>

Logik.io launches beta version of Cosmo AI

Technologies bringing about a new reality

Extended Reality

ANALYST_QUICK_TAKE

INCUMBENTS_PRESENT

<div>
 <p>Samsung introduced an OLEDoS (OLED on Silicon) screen designed for XR headsets at the Society for Information Display (SID) 2024 event. The screen is a 1.03-inch RGB OLED panel, developed by eMagin, with a pixel density of 3,500 ppi. It features a new Fine Silicon Mask (FSM) leading to a denser, more efficient pixel compared to the traditional Fine Metal Masks (FMM).</p>
</div> <p><b>Analyst QuickTake:<br>
</b> In <a href="https:<br>
//sp-edge.com/updates/18680"> May 2023 </a> , Samsung Display Solutions entered a definitive merger agreement with AR/VR display manufacturer eMagin valued at ~USD 218 million.&nbsp;Additionally, the company plans to <a href="https:<br>
//sp-edge.com/updates/27093"> debut </a> its mixed reality headset by 2025, developed in collaboration with Google and Qualcomm, which will likely feature eMagin’s displays as well.</p>

Samsung showcases OLEDoS screen for XR headsets at SID 2024 event

A new wave of meat, fish, and poultry alternatives are driving this hyper-growth industry into the mainstream.

Plant-based Meat

<div>
 <p>Tofurky, a subsidiary of Morinaga Nutritional Foods, aims to introduce plant-based hot dogs and a revised version of its deli slices for foodservice clients at the National Restaurant Association (NRA) show in Chicago.</p>
 <p>Primarily, the new hot dogs target entertainment entities like amusement parks and stadiums, offering a firm bite and a meaty, smoky texture. Conversely, the updated deli slices claim to closely mimic animal-based meats and offer 13 g of protein per serving. These two products are vegan and free from allergens, cholesterol, GMOs, gluten, and soy.</p>
</div> <p><b>Analyst QuickTake:<br>
 </b> In <a href="https:<br>
//sp-edge.com/updates/16403"> February 2023 </a> , Morinaga Nutritional Foods (MNF) acquired Tofurky from its parent company, Turtle Island Foods. This acquisition, built on a long-standing relationship between the companies, was to help MNF with its expansion plans in the US and beyond.</p>

Tofurky to unveil plant-based hot dogs and updates deli slices at NRA Show

<div>
 <p>LG Display, part of the LG Group, has announced a new micro-OLED display shown at SID Display Week 2024. The display features 4K resolution and 10,000 nit brightness.</p>
 <p>This new product has key features such as 4,000 pixels per inch density and a color gamut of 97% DCI-P3. These qualities surpass current devices like Apple Vision Pro with 3,700 micro-OLED displays. The display also offers double the brightness at 10,000 nits, compared to Sony's Vision Pro display which reportedly has 5,000 nits.</p>
 <p>The higher brightness levels of the display could reduce motion blur in headsets, even though the brightness is decreased a bit by the use of pancake lenses. </p>
 
</div> <p><b>Analyst QuickTake:<br>
</b> The news follows LG’s <a href="https:<br>
//sp-edge.com/updates/27052"> partnership </a> with Meta to launch an XR headset in 2025. The headset is likely to be a successor to Meta’s Quest Pro enterprise-focused headset, and will potentially utilize the new micro-OLED displays announced</p>

LG Display announces micro-OLED display with 4K resolution and 10,000 nit brightness

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 <p>The Hungary-based predictive biology simulation company, Turbine, has received an investment from Accenture Ventures. The financial details of the deal were not revealed. Turbine is part of Accenture's Project Spotlight, a program designed to offer financial and technical support to tech-based startups.</p>
 <p>Turbine aims to use this funding to broaden its services to international biopharma industries. The objective is to speed up their drug development processes by leveraging Turbine’s biological knowledge. </p>
 
</div>

Turbine secures investment from Accenture Ventures

A booming food and beverage segment with a history as rich and varied as its present-day product offerings.

Plant-based Dairy & Egg

<div>
 <p>Armored Fresh, a manufacturer of plant-based dairy alternatives, is preparing to introduce their new product, Oat Milk Cheddar Dip, at the National Restaurant Association Show in Chicago. This product is a dairy-free alternative to standard cheddar cheese sauces.</p>
 <p>The Oat Milk Cheddar Dip is directed towards foodservice clients and claims to offer a similar texture and melting capability as regular dairy products. Additionally, it is gluten-free, GMO-free, and cholesterol-free, making it suitable for vegans, vegetarians, and individuals with lactose intolerance.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> Armored Fresh, established in South Korea, entered the US market in 2022 and has garnered a significant sales presence with over 150 sales accounts. Its latest US <a href="https:<br>
//sp-edge.com/updates/26102"> collaboration </a> was with restaurant chain Bareburger to incorporate its zero-dairy Oat Milk Cheddar Cheese into Bareburger's menu offerings.</p>

Armored Fresh to launch Oat Milk Cheddar Dip at NRA Show

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

<div>
 <p>The US Food and Drug Administration (FDA) has awarded breakthrough designation to Karius for its DNA-based blood test, the Karius Test. Developed to detect nearly 1,000 different types of pathogens, the test has been commercially available since 2017 and is being utilized at around 400 locations across the US.</p>
 <p>The Karius Test finds its key application in cancer centers, where it is used to monitor patients with compromised immune systems who might have potentially fatal lung conditions. The test is capable of identifying various infectious agents such as bacteria, fungi, parasites, and viruses from blood samples. In clinical studies, it was able to ascertain the likely cause of pneumonia in 12% of patients tested.</p>
 <p>Karius, an entity operating in the life sciences sector, specializes in infectious disease diagnostics using genomic insights. Its Karius Test is a liquid biopsy test that can non-invasively detect close to 1,000 pathogens from just one blood sample. The test employs advanced genomics and artificial intelligence to analyze microbial cell-free DNA. This provides diagnostic information that can rapidly facilitate treatment decisions.</p>
</div>

Karius Receives FDA breakthrough designation for its DNA-based blood test

<div>
 
 <p>Metabolon, a metabolomics service provider, recently closed a credit facility led by Trinity Capital, bringing in USD 60 million. This comes soon after a previous investment round in January 2023 which raised USD 25 million. An upfront payment of USD 42.5 million was made at the closing of the new round. Metabolon plans to use the funds to boost its R&amp;D capabilities, upgrade its metabolomics platform, enter new markets and establish strategic partnerships.</p>
 <p>Metabolon offers in-depth biochemical data and insights that are utilized in various scientific and clinical studies. Its proprietary Metabolon Discover global discovery panel is reportedly capable of detecting and identifying more than 5,400 metabolites in any biological sample via its metabolite library, making it the largest in the industry. The company's key services for the biopharma industry include biomarker discovery, target identification, pharmacokinetics, and growth media analysis.</p>
 
</div>

Metabolon raises USD 60 million in debt financing to strengthen R&D capabilities and enhance metabolomics platform

<div>
 <p>Accelerated Biosciences is partnering with Spanios tumor therapy research firm to develop cancer therapeutics using its human trophoblast stem cell (hTSC) platform. The goal is to merge Spanios' COMPASS platforms and patient-derived tumor models with AcceleratedBio's hTSC platform for better therapy designs particularly for solid tumor cancers. Accelerated Biosciences will provide ethically sourced pluripotent stem cells for diverse medical and biotech uses. Spanios will use its expertise in tumoroid research to swiftly model preclinical therapeutic performances and generate relevant clinical data for these stem cells. This aims to improve cell-based therapies, particularly for tough cancers like Ovarian and Colorectal. </p>
 <p>Spanios is a precision oncology company that uses its unique patient-derived 3D tumoroid (PDT) platform to study the biological complexity of solid tumors for developing treatments. The platform replicates host tumor environments and allows customizable testing conditions to study drug responses and efficacy.</p>
 </div>

Accelerated Biosciences and Spanios partner to advance therapeutic design in solid tumor cancers

<div>
 <p>Telo Genomics has formed a partnership with Emery Pharma to combine their technologies and offer clinical research and development solutions to their clients in the pharmaceutical and diagnostics sectors.</p>
 <p>This collaboration aims to improve their capacity to give cellular and molecular bioanalytical solutions. Telo Genomics is contributing its TeloView platform, which can identify genomic instability, while Emery Pharma is contributing services like mass analysis, peptide mapping, glycan analysis, post-translational modifications, immunogenicity analysis, as well as general research and development and good laboratory practice support.</p>
</div>

Telo Genomics and Emery Pharma put together their technologies to provide clinical R&D solutions

<div>
 <p>UK-based biotech company Oxford Biodynamics (OBD) has joined forces with King's College London to capitalise on its EpiSwitch technology in the treatment of rheumatoid arthritis (RA), subsequent to a successful APIPPRA trial of the biological therapy Abatacept. This therapy strives to fight arthritis by pinpointing the root of inflammation.</p>
 <p>Through OBD’s unique EpiSwitch platform, the partnership aims to pinpoint high-risk RA patients who could see benefits from Abatacept treatments. EpiSwitch, an epigenetic platform, has the ability to identify and authenticate biomarkers for a range of diseases, including cancer, as well as autoimmune and neurodegenerative conditions. It has been reported that the APIPPRA trial showcased encouraging results, with a noteworthy 92.8% of patients who underwent Abatacept therapy maintaining an RA-free status after a year.&nbsp;</p>
 <p>Positioned in the UK, Oxford BioDynamics specialises in the development of precision medicine tests, delivered through its patented EpiSwitch 3D genomics platform. This platform affords the creation of molecular diagnostic classifiers, designed for a variety of uses, such as predicting drug response, patient diagnosis, and prognosis. Included in OBD’s headline products are EpiSwitch CiRT (devised for the prediction of cancer immunotherapy responses), EpiSwitch PSE (Prostate Screening Test), EpiSwitch CST (Covid Severity Test), and the EpiSwitch Explorer for 3D genome profiling.</p>
 </div>

All Updates

Logik.io launches beta version of Cosmo AI

Samsung showcases OLEDoS screen for XR headsets at SID 2024 event

Tofurky to unveil plant-based hot dogs and updates deli slices at NRA Show

LG Display announces micro-OLED display with 4K resolution and 10,000 nit brightness

Turbine secures investment from Accenture Ventures

Armored Fresh to launch Oat Milk Cheddar Dip at NRA Show

Karius Receives FDA breakthrough designation for its DNA-based blood test

Metabolon raises USD 60 million in debt financing to strengthen R&D capabilities and enhance metabolomics platform

Accelerated Biosciences and Spanios partner to advance therapeutic design in solid tumor cancers

Telo Genomics and Emery Pharma put together their technologies to provide clinical R&D solutions

Oxford Biodynamics partners with KCL to enhance rheumatoid arthritis treatment using EpiSwitch technology

Sales Engagement Platforms

Logik.io launches beta version of Cosmo AI

Contact us